Letrozole
Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. (In Vitro) :Letrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner.Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation.Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells (In Vivo) :Letrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats.
Product Specifications
CAS Number
112809-51-5
Product Name Alternative
CGS 20267
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO: 57 mg/mL (199.78 mM)
Smiles
N#CC1=CC=C (C (C2=CC=C (C#N) C=C2) N3N=CN=C3) C=C1
Molecular Formula
C17H11N5
Molecular Weight
285.3
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
4-[ (4-cyanophenyl) - (1,2,4-triazol-1-yl) methyl]benzonitrile
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
COP1, NT (CARD16, COP, COP1, Caspase recruitment domain-containing protein 16, CARD only domain-containing protein 1, Caspase-1 inhibitor COP, Pseudo interleukin-1 beta converting enzyme) (APC) discontinued
Sin3a, CT (Sin3a, Kiaa4126, Paired amphipathic helix protein Sin3a, Histone deacetylase complex subunit Sin3a, Transcriptional corepressor Sin3a) (MaxLight 650) discontinued